Among newborns every year, diseases such as congenital malformations, congenital diseases, and genetic diseases have high morbidity and mortality. In recent years, non-invasive prenatal diagnosis (NIPD) has been widely used due to its advantages of non-invasiveness, high accuracy, and limited gestational age. NIPD has increased the probability of detecting congenital and genetic diseases and provided sufficient protection for eugenics and population quality. Hence, NIPD has become the preferred method of prenatal diagnosis at home and abroad. However, the current biomarkers used in prenatal diagnosis cannot comprehensively and accurately diagnose these diseases in the fetus. Therefore, finding simpler and more effective biomarkers for early prenatal diagnosis is crucial. Exosomes contain nucleic acids (including DNAs, miRNAs, circRNAs, lncRNAs, etc.), proteins, and lipids. A large number of studies have found that fetal-derived exosomes can pass through the placenta and be released into the maternal circulation in large quantities, which is an important tool for communication between the peripheral blood of pregnant women and the placenta. Therefore, exosomal contents in the peripheral blood of pregnant women have great application prospects in non-invasive prenatal diagnosis. Creative Biolabs is a world-leading exosome service provider, which can provide customers with the most powerful biomarker discovery service and help promote the development of exosomes in non-invasive prenatal diagnosis.
Fig.1 Trafficking and production of extracellular vesicles by the placental syncytiotrophoblast.1,2
In addition to the above-mentioned peripheral blood of pregnant women, the amniotic fluid of pregnant women also contains a large number of fetal-derived exosomes, which also has great potential in prenatal screening. The following is a summary of potential prenatal biomarkers in exosome that have been identified in current research.
Source of exosomes | Prenatal biomarkers in exosome | Changes of prenatal biomarkers in exosome | Possible diseases |
Plasma from pregnant women | hsa-piR-009228, hsa-piR- 016659 and hsa-piR-020496 | Up-regulated | Fetal nonsyndromic cleft lip and palate |
Plasma from pregnant women | hsa-let-7a-3p | Down-regulated | Fetal nonsyndromic cleft lip and palate |
Serum from pregnant women | coronin 1A and dynamin 2 | Down-regulated | Fetal neural tube defect |
Serum from pregnant women | Lactoferrin | Down-regulated | Fetal ventricular septal defect |
Serum from pregnant women | hsa-miR-146a-5p | Down-regulated | Fetal ventricular septal defect |
Amniotic fluid | hsa-miR-300 and hsa-miR-299-5p | Down-regulated | Fetal congenital obstructive nephropathy |
Serum from pregnant women | miR-378d, miR-100-5p and miR -215-5P | Up-regulated | Ectopic Pregnancy |
If you want to discover potential prenatal biomarkers in exosomes, please contact us without hesitation to leave your needs and contact information. You may provide consented samples from pregnant women, such as peripheral blood, amniotic fluid, or other bodily fluids. At Creative Biolabs, our professional scientific consultants will formulate rigorous experimental protocols and provide one-stop technical services for you to help you discover the most promising prenatal exosome markers.
References